|
|
Home | Submit Press Release | Advertise | Submit Website
(CityRegions.Com, August 24, 2017 ) Description:
Pruritus Pipeline Review, H2 2017, provides an overview of the Pruritus (Dermatology) pipeline landscape.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/385741 .
Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Pruritus Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pruritus (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pruritus (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 12, 6, 1 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Pruritus (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus (Dermatology).
The pipeline guide reviews pipeline therapeutics for Pruritus (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Pruritus (Dermatology) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Pruritus (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Pruritus (Dermatology)
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/385741 .
Reasons to buy
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Pruritus (Dermatology).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Pruritus (Dermatology) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned:
Albireo Pharma Inc
Allergan Plc
Amorepacific Corp
Asana BioSciences LLC
Cara Therapeutics Inc
Celgene Corp
Chugai Pharmaceutical Co Ltd
ELORAC Inc
GlaxoSmithKline Plc
Hydra Biosciences Inc
J Uriach Y Compania SA
NeuroCycle Therapeutics GmbH
Patagonia Pharmaceuticals LLC
Patara Pharma Inc
Phosphagenics Ltd
RDD Pharma Ltd
Sanwa Kagaku Kenkyusho Co Ltd
Shionogi & Co Ltd
Sienna Biopharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Teikoku Pharma USA Inc
Tesaro Inc
Tioga Pharmaceuticals Inc
Toray Industries Inc
Vanda Pharmaceuticals Inc
For any enquires before buying, connect with us @ enquiry@orbisresearch.com
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Us:
Hector Costello
Senior Manager Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For more information contact sales@orbisresearch.com
Orbis Research
Hector Costello
+1 (214) 884-6817
sales@orbisresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
